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New criteria for the diagnosis of Alzheimer’s disease (AD) based on biomarker results have
recently been developed and are currently undergoing extensive validation. The next few
years may represent a time window where the diagnostic validity of biomarkers will be
studied in highly specialized research settings. Biomarkers results will be used to direct
clinical diagnosis and, whenever appropriate, therapy and management.This piece aims to
stimulate discussion by identifying the ethical challenges involved in the use of biomarkers
to make a diagnosis of mild cognitive impairment due to AD and disclose it to patients.
At the individual level, these challenges are related to (i) the ethical appropriateness of
implementing an ecological diagnostic research protocol, (ii) the related informed consent
process, and (iii) the diagnostic disclosure.We justify the ethical legitimacy of implementing
a research diagnostic protocol by referring to the respect of patients’ subjectivity and
autonomy, and we suggest guidelines for informed consent development and diagnostic
disclosure. All of the above points are discussed in light of the unique features of
AD, currently scanty treatment options, and knowledge and uncertainties regarding the
diagnostic value of biomarkers.
Keywords: prodromalAlzheimer’s disease, informed consent, diagnosis disclosure, translational research, bioethics
guideline
INTRODUCTION
The collection of evidence regarding the validity of biomarkers for
disease detection is a dynamic process that will remain on-going
until sufﬁcient evidence has accumulated to satisfy the restrictive
standards for widespread routine clinical use. New criteria for the
diagnosis of Alzheimer’s disease (AD) based on biomarker data
have been developed by an International Working Group in 2007
(Dubois et al., 2007, 2010) and the National Institute on Aging
andAlzheimer’s Association task force in 2011 (Albert et al., 2011).
These criteria posit that AD can be diagnosed at themild cognitive
impairment (MCI) – or predementia/prodromal – stage through
the assessment of so-called core biomarkers, including medial
temporal atrophy on high-resolutionmagnetic resonance imaging
(MRI), temporoparietal hypometabolism on ﬂuorodeoxyglucose
positron emission tomography (FDG-PET), Abeta42 and tau in
the cerebrospinal ﬂuid (CSF), and increased cortical uptake of
amyloid ligands on PET. Preliminary but consistent evidence
has been collected regarding the diagnostic validity of core AD
biomarkers, i.e., their ability to detect subjects with mem-
ory impairment who have a high likelihood of exhibiting AD
pathology and therefore progressing to dementia.
The authors of the new criteria and the scientiﬁc commu-
nity at large advise that validation studies are needed for a more
accurate estimate of the biometric features of biomarkers (sensi-
tivity, speciﬁcity, positive predictive value, and negative predictive
value). Moreover, the criteria have not been operationalised,
i.e., it has not yet been established how biomarkers should be
combined into a diagnostic algorithm, and measurement pro-
cedures, norms, and normality thresholds have not yet been
standardized. To date, AmyvidTM (Florbetapir F 18 injection)
PET ligand has been approved by US and European agencies
and VizamylTM (Flutemetamol F18 injection) by US FDA for β-
amyloid plaque density imaging in adult patients with cognitive
impairment.
With this imaging protocols, a negative scan result greatly
reduces the likelihood that a patient’s cognitive impairment is due
to AD, while a positive scan enhances the likelihood of but does
not establish a deﬁnitive diagnosis of AD.
The evidence required for conﬁrmation of biomarker validity
will be collected in highly specialized research settings through
standardization of collection and measurement practices as well
as collection of empirical data on the diagnostic accuracy of indi-
vidual biomarkers and the incremental accuracy of combined
biomarkers. In this phase, which might last a few years, ecological
diagnostic research protocols will need to be developed and car-
ried out that leverage on biomarker results. Thus, biomarkers will
be collected, a judgment of normality/abnormality will be made
based on pre-deﬁned thresholds, the results will be compounded
into a judgment of presence or absence of MCI due to AD, and
the latter judgment will be delivered to the patient. The research
aspect of the protocol will consist of controlling the procedures
and outcomes of each of the above steps.
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The related ethical issues deserve to be discussed. At the indi-
vidual level, these issues relate to (i) whether implementing a
diagnostic research protocol is ethically appropriate in the ﬁrst
place, and, if so, (ii) the development of a pertinent informed
consent process and (iii) the appropriate diagnostic disclosure.
The aim of this paper is to stimulate discussion in the com-
munity by indicating the ethical challenges involved in using
biomarkers to make and disclose a diagnosis of MCI due to AD to
patients in the clinical practice, and suggest possible operational
guidelines.
THE ETHICAL APPROPRIATENESS OF IMPLEMENTING A
DIAGNOSTIC RESEARCH PROTOCOL
When facing the possibility of diagnostic use of biomarkers, the
ﬁrst ethical question relates to the appropriateness of implement-
ing a diagnostic research protocol in which patients are offered
access to a biomarker-based diagnosis. This is a major issue due
to: the experimental nature of the procedure; the pre-disability
stage of the disorder which implies the predictive nature of the
diagnostic communication; the current lackof effective prevention
and treatment options; the concern about“catastrophic reactions”;
and the risk of stigmatization and misuse of diagnostic results by
third parties (such as employers and insurance agencies; Gauthier
et al., 2011; Karlawish, 2011; Prvulovic and Hampel, 2011). The
answer to this fundamental questionmay be found by delving into
patients’ requests. A typical case illustration might help to better
clarify the point.
Patients with suspected MCI due to AD are generally
(self-)referred to amedical service for memory problems, request-
ing specialist consultation. Clinical and cognitive assessments
may reveal preservation of daily function associated with signiﬁ-
cant episodic memory impairment. Secondary causes of cognitive
impairment (depression, iatrogenic effects, brain tumor, cere-
brovascular disease, and others) are excluded. The patient is
typically given a syndromic diagnosis of amnestic MCI (Petersen
et al., 1999). Lacking access to biomarker assessment, the “diag-
nosis” of MCI is the only possible outcome of the consultation,
and the patient is informed accordingly. However, it should be
stressed that MCI is not a disease, in that it can be underlined by
a number of diseases, including AD. It is well known that between
one half and two thirds of MCI patients have AD, while the rest do
not have progressive conditions and can even improve (Bennett
et al., 2002). Thus, the communication of a “diagnosis” of MCI is
uninformative to the patient, and it can even increase confusion
about health status (Whitehouse et al., 2004).
Academic memory clinics aiming to validate diagnostic
biomarkers have two options: (i) a purely scientiﬁc research pro-
tocol, in which biomarker data are collected for the purpose of
biomarker standardization and validation, but patients are given
no feedback on biomarker results; or (ii) an “ecological” diagnos-
tic research protocol, in which biomarker data are collected for
biomarker standardization and validation and patients are given
feedback on biomarker results as well as an etiologic diagnosis. In
the ﬁrst case, data will be analyzed in an aggregate manner and no
result will be studied with regard to the individual patient, while
in the second case, data will also be analyzed on an individual basis
to make a diagnosis. Importantly, case (i) excludes case (ii), but
not vice versa.
At the present state of knowledge, bothoffering andnot offering
the opportunity to take part in a diagnostic research protocol has
ethical implications, and the pros and cons need to be balanced
(Table 1).
The boundary between translational research and clinical prac-
tice can indeed be fuzzy, especially in the case of disorders with
a pathogenesis that is still unclear and disorders for which effec-
tive treatments are still not available (Porteri et al., 2010). Thus,
despite the fact that biomarkers are currently under study to
ensure their validation and do not yet meet the strict require-
ments for use in routine practice, the careful use in a clinical
context of research results that have already reached a sufﬁ-
ciently high degree of reliability can be in the patient’s interest
more than choosing not to use them until full evidence is
collected.
The strong ethical reason in favor of offeringpatients theoppor-
tunity to take part in a diagnostic research protocol is that patients
refer to memory clinics with a medical problem asking for a diag-
nosis, and the use of biomarkers enhances physicians’ ability to
make a more accurate diagnosis. The main ethical justiﬁcations
for offering participation in a diagnostic research protocol include
the respect for the patients regarded as autonomous subjects enti-
tled to ask, know, and make decisions about their health and life;
and the fact that biomarker assessment can provide incremental
information. Currently, biomarker assessment can only be per-
formed in a research context, and accepting the risks attached
to a diagnosis that is made before the biomarker-based diagnosis
is a routine procedure. Furthermore, a biomarker-based diagno-
sis can help patients plan for the future in terms of caregiving,
health care choices, and ﬁnancial and legal decisions, but does
not provide immediate increased possibilities for treatment and
prevention.
Table 1 | Pros and cons of implementing a diagnostic research protocol based onAlzheimer’s biomarker assessment in MCI patients.
Cons Pros
- Experimental nature of biomarker assessment
- Pre-disability stage of the disorder and predictive nature of the diagnosis
- Lack of effective prevention and treatment options
- Concern about “catastrophic reactions”
- Risk of stigmatization and misuse of diagnostic results by third parties
- Robust scientiﬁc evidence has demonstrated the diagnostic value of
biomarkers
- Respect for the patient’s wish to know what is going on in his/her brain
- Ability to plan for the future
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At this point, how to offer the subject the opportunity for a
biomarker-based diagnosis is key. Respect for patient autonomy
requires that the patient is given all information to consolidate
his/her wish to know and is afforded the ability to change his/her
mind and autonomously choose the best option.
INFORMED CONSENT PROCESS FOR A BIOMARKER-BASED
DIAGNOSIS
Given the above context, the informed consent process is a key ele-
ment in biomarker assessment and deserves speciﬁc attention to
ensure that the subject is fully able to understand the information
regarding the diagnostic research protocol and to decide if he/she
really wishes to undergo the evaluation and receive the results.
Clariﬁcation of the issues at hand from the very beginning of the
biomarker assessment process is mandatory to avoid damage and
to maximize patient beneﬁt. The experimental nature of the pro-
cedure makes the process of informed consent even more critical
than it is in clinical routine practice, as the risks/beneﬁts ratio is
likely to be higher for procedures that have not been fully vali-
dated. Patients need to be aware of the experimental nature of the
diagnostic examinations and of the value of the results that can
be expected. In particular, the relatively uncertain nature of the
diagnosis due to the need for further validation of the biomarkers
should be explained in a realistic and understandable way to avoid
confusion and misunderstandings.
We suggest that the information provided to patients should
include the following essential elements (Table 2):
(A) THE RESEARCH NATURE OF THE DIAGNOSTIC PROTOCOL
The subject needs to be aware of the research nature of the diag-
nostic protocol, i.e., the fact that a biomarker-based diagnosis is
not yet part of clinical routine practice and biomarker validity is
still under study. The physicianwill explain that the scientiﬁc com-
munity believes that biomarkers are potentially useful formaking a
more accurate and informed etiologic diagnosis than one of MCI.
In particular, the scientiﬁc community anticipates that biomarker
results can be used to discriminate between people who will and
will not develop Alzheimer’s dementia. The physician will refer to
previous studies showing that an individual biomarker abnormal-
ity has a high predictive value (Hansson et al., 2006;Mattsson et al.,
2009) for the development of Alzheimer’s dementia within 5 years.
The physician will explain that data are incomplete regarding the
Table 2 | Key elements of the informed consent process.
(a) The research nature of the diagnostic protocol
(b)What the subject will be asked if he/she chooses to participate
(c)What the individual subject can expect
(d) The uncertainty of the diagnosis of MCI due to AD
(e) The personal beneﬁt of receiving the diagnostic results
(f) The right to privacy
(g) Non-participation or withdrawal from the research project
(h) The option of sharing the result with the family
(i) The option to not receive the diagnostic results
diagnostic accuracy of individual biomarkers and the incremen-
tal accuracy of combined biomarkers; however, it is quite likely
that two or more abnormal markers will signiﬁcantly enhance the
predictive power (Frisoni et al., 2010; Prestia et al., 2013).
(B) WHAT THE PATIENT WILL BE ASKED IF HE/SHE CHOOSES TO
PARTICIPATE
The physician will explain what each biomarker examination
entails, taking into account risks, burden, and discomfort asso-
ciated with the procedures.
(C) WHAT THE INDIVIDUAL SUBJECT CAN EXPECT
The physician will provide information on what can be expected
from the study in terms of results that are relevant to the indi-
vidual participant. Using a variable combination of biomarkers,
a diagnosis of MCI due to AD could be made for the individual
patient if the test results are positive. Alternatively, the diagnosis
of AD could be excluded in those who test negative for the relevant
biomarkers. The possibility that the results will not be informative
also needs to be mentioned.
(D) THE UNCERTAINTY OF THE DIAGNOSIS OF MCI DUE TO AD
The uncertainty of the diagnosis of MCI due to AD needs to
be emphasized. On the one hand, the diagnostic validity of the
biomarkers is highly probable, but it requires ﬁnal demonstra-
tion in multiple large representative cohorts. This implies that the
diagnostic use of biomarkers does not allow the formulation of a
ﬁnal diagnosis but rather a diagnosis with a high degree of con-
ﬁdence, particularly when the biomarkers are used together and
the results are concordant. On the other hand, the diagnosis is
expressed in terms of the probability rather than the certainty of
developing Alzheimer’s dementia within ﬁve years from the ﬁrst
assessment.
(E) THE PERSONAL BENEFIT OF RECEIVING THE DIAGNOSTIC RESULTS
The physician will explain to the subject the potential bene-
ﬁts arising from the disclosure of the diagnosis. These beneﬁts
include allowing those involved to make decisions on signiﬁ-
cant matters and to plan for the future. On the other hand,
as far as a cure is concerned, the utility of knowing the diag-
nosis in advance is debatable at the present moment and is
a matter of subjective judgment. No effective disease mod-
iﬁer is available for AD. Current drugs (i.e., cholinesterase
inhibitors and memantine) can provide symptomatic relief in
a number of patients but cannot delay disease progression.
Unfortunately, these drugs, along with cognitive training and
rehabilitation, for which there is still no indication of any signif-
icant beneﬁt (Bahar-Fuchs et al., 2013), are the only real options
today. It is reasonable to assume that starting treatments at
a very early stage of the disease can result in better success
both in terms of biological changes and clinical improvement
(Gauthier and Leuzy, 2010; Prvulovic and Hampel, 2011); how-
ever, this hypothesis needs to be proven in clinical trials with new
drugs.
(F) THE RIGHT TO PRIVACY
The subject needs to be aware that every effort will bemade to keep
personal data conﬁdential, according to the human being’s right to
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respect for private life and to local legislation. This will guarantee
that third parties, such as employers or insurance agencies, will
not be able to access subjects’ data and use these data against the
subjects’ interests.
(G) NON-PARTICIPATION OR WITHDRAWAL FROM THE RESEARCH
PROJECT
The subject needs to be aware that he/she is not obliged to take part
in the research diagnostic protocol and is free to withdraw from
the protocol at any time, without having to provide a reason. The
subject also needs to know that this decision will not in any way
affect the relationship with the physician, although it will prevent
the use of biomarkers to aid the diagnostic procedure.
(H) THE OPTION OF SHARING THE RESULT WITH THE FAMILY
The subject will be offered the option of sharing the informa-
tion regarding the biomarker assessment as well as the disclosure
of the diagnosis with a family member. The subject will also
have the opportunity to delegate a family member to receive the
examination results.
(I) THE OPTION TO NOT RECEIVE THE DIAGNOSTIC RESULTS
The subject could be offered the opportunity to take part in the
research protocol while deciding at the same time not to receive
the experimental diagnostic results. In any case, he/she will retain
the option of changing his/her mind throughout the biomarker
assessment process and during medical follow-up.
Some of the above elements (a, c, d, e) are speciﬁc to the
case under discussion, some are common to informed consent
for research protocols in general (b, f, g), and others are common
to diagnostic disclosure in general (h, i). All are essential elements
that should be part of the information provided to the subject
within a patient–physician relationship. The clinician should be
able to adapt the information to the particular subject according
to the subject’s speciﬁc circumstances, educational background,
and ability to understand. The breadth of information that the
physician will provide will need to be tailored to the individual
patient’s ability to understand, ensuring that the subject will be
offered the maximum level of information complexity he/she can
retain. The verbal communication of information by the clin-
ician is paramount and requires plenty of time to explain and
answer questions and the ability to speak simply while not deny-
ing that there are unsolved issues together with the sensitivity to
understand the subject’s expressed and unexpressed wishes.
The proposal relies on current knowledge and needs to be
revised as new scientiﬁc evidence becomes available.
DIAGNOSTIC DISCLOSURE OF MCI DUE TO AD
The disclosure of the diagnosis of Alzheimer’s dementia is
difﬁcult and complex even when the diagnosis is based on
widely validated and internationally employed criteria. Guide-
lines for the disclosure of the diagnosis emphasize that
telling the patient the truth in a sensitive way and avoid-
ing unnecessary despair should be the usual practice to allow
preservation of the patient’s quality of life and to play an
active role in planning the future (Alzheimer Europe, 2009;
Alzheimer’s Association, 2011).
Nevertheless, the guidelines are general, and there is wide
variability in physicians’ attitudes and behaviors (Bamford et al.,
2004; Werner et al., 2012); thus, practices based on local cul-
tural values and preferences often prevail. In the case of the
diagnosis of MCI due to AD based on the revised criteria, diag-
nostic disclosure is made even more difﬁcult because the validity
of these criteria is still under study (Porteri et al., 2010; Visser
et al., 2012; Gauthier et al., 2013). Further elements of complex-
ity for the physician relate to the generally greater awareness of
patients with MCI compared to those with AD and the frequent
lack of a family member with whom to share the burden of
communication.
As a general rule, if a patient decides to undergo the diagnostic
research protocol after all the information is provided, he/she is
already aware of what can be expected as a diagnostic result at the
end of the examinations. Nevertheless, additional issues need to
be taken into consideration in the diagnostic disclosure of MCI
due to AD (Table 3).
THE THERAPEUTIC PRIVILEGE IN SITUATIONS OF CLINICAL
UNCERTAINTY
The element of “clinical uncertainty” is currently a peculiarity
of the diagnosis of MCI due to AD. Apart from this element,
with regard to the reasons for and against diagnosis communi-
cation, the disclosure of MCI due to AD does not differ from the
disclosure of Alzheimer’s dementia in a stage when the patient
has preserved reasoning and judgment. Indeed, Alzheimer’s
dementia can be diagnosed in patients with global cognitive
performance in the MCI range. The core of the physician’s
disclosure is in fact the future development of dementia, i.e.,
disability, in a context of progressive cognitive and functional
deterioration. Several reasons for and against the disclosure of
an AD diagnosis are reported in the literature and experienced
in clinical practice. The most important reasons for disclosing
the diagnosis to patients involve the patient’s “right to know
the truth” and the need to allow the patient to plan for the
future. The principle of respect for autonomy plays a major
role in decision-making with respect to disclosure. The most
important reasons against disclosing the diagnosis of AD to
patients are related to concerns about harming the patient and
the intention to protect the patient from potentially adverse psy-
chological reactions, including anxiety, depression, catastrophic
thinking, suicidal ideation, and suicide. The principle of non-
maleﬁcence/beneﬁcence plays a major role in deciding against full
disclosure.
We suggest that the concept of therapeutic privilege be seriously
taken into consideration in the disclosure of MCI due to AD. The
concept applies to situations in which full preservation of both the
Table 3 | Issues to be considered in the diagnostic disclosure of MCI
due to AD.
–The therapeutic privilege in situations of clinical uncertainty
– Cases that justify delayed diagnostic disclosure
– The role of the subject’s family
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principle of autonomy and the principle of beneﬁcence seems to
be impossible and the doctor, caught between the need to inform
the patient and the wish to ensure the patient’s well-being bymini-
mizing suffering, feels the obligation to renounce full disclosure to
safeguard the patient’s well-being (Richard et al., 2010). Referring
to the therapeutic privilege seems evenmore pertinent in biomed-
ical research than in medical practice, given the different degree of
uncertainty that further complicates the concept of the “right to
know the truth.”
CASES THAT JUSTIFY DELAYED DIAGNOSTIC DISCLOSURE
Patients who, even after adequate treatment, show symptoms
of anxiety and depression and subjects without family support
are subjects for whom the therapeutic privilege may apply; in
these cases, a delay in diagnostic disclosure may be acceptable.
Although the psychological risks tied to the disclosure of an AD
diagnosis (Draper et al., 1998; Carpenter et al., 2008) will require
further studies, it is wise to consider that symptoms of anxiety
and depression may increase in people who receive a diagnosis of
MCI due to AD. Diagnostic disclosure could cause a worsening in
the patient’s quality of life that cannot be balanced by the respect
for the patient’s autonomy. On the contrary, patients’ autonomy,
i.e., the ability to manage their own life, could even be put at
risk by the disclosure. Similarly, subjects without family support
and those who lack close persons with whom to share informa-
tion and disease experience are in a situation of frailty, and the
risk that they will not to be able to cope with the disclosure is
higher. To preserve their psychological andmoral integrity, a delay
in disclosure may be required. During this time, the patient is
invited to involve a trusted person in the diagnostic disclosure,
and additional psychological support is put in place.
Other patients who require a delay in diagnostic disclosure are
thosewhoclearly show that theydonotwish to know thediagnosis.
Their wish must always be respected, as it is the patient’s right –
but not his/her duty – to be aware of information related to his/her
health and life.
In all these cases, the physician, without deceiving the patient,
will provide only a strict amount of information that the sub-
ject can cope with (Whitehouse et al., 2004). A delay in complete
communication of the results is justiﬁed for several reasons.
First, the decision to not provide all the information to the
patient at the time of the assessment does not preclude the possi-
bility of further discussion between the physician and the patient,
during which new elements can be added once the patient is ready
to cope with the information. The nature of the diagnosis of MCI
due to AD actually gives the physician the chance to review infor-
mation over a period of time based on the patient’s condition and
wishes. In the meantime, the subject’s features can also be better
deﬁned, still persisting a full patient’s competence. The physician
will schedule frequent follow-up visits to be able to monitor the
evolving situation. Moreover, it is important to stress that, due to
the lack of effective treatments, the delay in delivering information
does not delay the option of treatment for the subject.
THE ROLE OF THE SUBJECT’S FAMILY
Within the context of diagnostic disclosure, the role of a patient’s
family differs from country to country on the basis of local social
structure and cultural heritage. In some countries, such as Italy
(Pucci et al., 2003), family members usually play a very impor-
tant role in the process of diagnostic disclosure to the point
where they often ask to receive the diagnosis before their rela-
tive and to play an active role in the diagnostic disclosure to the
patient. This clearly helps the physician in the difﬁcult task of
communicating bad news and, at the same time, provides the
family members with the information they need to understand
the disease, to plan for the patient’s care, and to cope with the
psychological and physical burden caregivers must carry during
the years of the patients’ cognitive and behavioral deterioration.
Within the context of MCI due to AD, it is quite common for
the patient to autonomously decide to attend the memory clinic
alone. We suggest that physicians always explore the patient’s
availability to involve a family member or a close friend in the
diagnostic process whenever possible. This involvement can both
provide the patient with the necessary support during and after
the diagnostic disclosure and allow the family to understand the
situation and assist in making lifestyle choices. For these reasons,
an option for the patient to share the diagnostic disclosure with
a family member should be included in the informed consent
process.
A further option to delegate a family member to receive com-
munication should be discussed, and the physician should explore
the possibility of talking to a family member. There may be sit-
uations in which communicating the probable diagnosis to the
subject at the time of assessment is not suggested, as in the case
of patients who show symptoms of anxiety and depression or
patients who do not wish to know, but knowledge of the examina-
tion results is important and useful for the care of the subject and
for the family organization.
CONCLUSION
We have discussed the ethical issues related to the diagnostic
use of biomarkers during a time in which biomarkers are still
being validated. After justifying the ethical legitimacy of imple-
menting a research diagnostic protocol, we have suggested a
guideline for informed consent and diagnostic disclosure, tak-
ing into consideration what is known and what is not known
about the value of the biomarkers as well as the peculiar fea-
tures of the disease and treatment options. The Alzheimer’s
clinical community and scientiﬁc societies, as well as patients’
associations, may wish to heed these early suggestions and thor-
oughly discuss them with the aim of developing widely shared
guidelines.
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